



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

OXFORD et al

Atty. Ref.: 620-288

Serial No. 10/766,030

Group: Unassigned

Filed: January 29, 2004

Examiner: Unassigned

For: EP4 RECEPTOR ANTAGONISTS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 27, 2004

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.


This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier];
and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith;
and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.


By: _____



B.J. Sadoff

Reg. No. 36,663

BJS:pp
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100



OXFORD et al
Serial No. 10/766,030

Sheet 1 of 2

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-288

10/766,030

APPLICANT

OXFORD et al

(Use several sheets if necessary)

FILING DATE

GROUP

January 29, 2004

Unassigned

FOREIGN PATENT DOCUMENTS

DOCUMENT		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES
	WO 00/18405	04/2000	WIPO			
	WO 01/72302	10/2001	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	BERGE, et al., "Pharmaceutically Acceptable Salts", <u>J. Pharm. Sci.</u> , 1977, Vol. 66, pp. 1-19
	ARUNLAKSHANA, O., et al., "Some quantitative use of drug antagonists", <u>Brit. J. Pharmacol.</u> , 1959, Vol. 14, pp. 48-58
	PORRETTA, G. C., et al., "Research on antibacterial and antifungal agents", <u>Il Farmaco, Ed. Sc.</u> , 1987, Vol. 42, No. 9, pp. 629-39
	MODRAKOWSKI, C., et al., "Synthesis of Pyrene Containing Building Blocks for Dendrimer Synthesis", <u>Synthesis</u> , 2001, No. 14, pp. 2143-2155
	WENKERT, E., et al., "Polyene Synthesis. Ready Construction of Retinol-Carotene Fragments, (\pm)-6(E)-LTB ₃ Leukotrienes, and Corticocin", <u>J. Org. Chem.</u> , 1990, Vol. 55, No. 25, pp. 6203-14
	BURES, E., "Regioselective Preparation of 2,4-, 3,4-, and 2,3,4-Substituted Furan Rings.", <u>J. Org. Chem.</u> , 1997, Vol. 62, No. 25, pp. 8741-49
	WANG, Y., et al., "A simple synthesis of fluoroalkyl substituted dihydrofurans by rhodium(II)-catalysed 1,3-dipolar reactions", <u>Tetrahedron</u> , 2001, Vol. 57, No. 16, pp. 3383-87
	BIN, Y., "A Concise Synthesis of the Differentiating Antibiotic L-Azatyrosine", <u>J. Org. Chem.</u> , 1995, Vol. 60, No. 8, pp. 2640-1
	DOLL, M. H., et al., "Irreversible Enzyme Inhibitors. Inhibitors of Guinea Pig Complement Derived by Quaternization of Substituted Pyridines with Benzyl Halides", <u>J. Med. Chem.</u> , 1976, Vol. 19, No. 9, pp. 1079-88
	MNDZHOYAN, A. L., et al., <u>Doklady Akademii Nauk Armyanskoi SSR</u> , 1957, Vol. 25, pp. 277-80
	VALENTA, M., et al., "Experiments in the furan series. III. Preparation of some 2,3,5-trisubstituted derivatives", <u>Collection Czechoslov. Chem. Commun.</u> , 1964, Vol. 29, pp. 1577-81
	ChemBridge Product List (17 Jan 2002): Order No. 5929447; CAS Registry No. 383379-03-01
	ChemBridge Product List (17 Jan 2002): Order No. 5930664; CAS Registry No. 339253-95-01
	ChemBridge Product List (17 Jan 2002): Order No. 6059629; CAS Registry No. 333352-32-02
	ChemBridge Product List (17 Jan 2002): Order No. 5404459; CAS Registry No. 331670-05-04
	ChemBridge Product List (17 Jan 2002): Order No. 5404452; CAS Registry No. 331670-03-02
	ChemBridge Product List (17 Jan 2002): Order No. 5924300; CAS Registry No. 297137-48-05
	ChemBridge Product List (17 Jan 2002): Order No. 5669841; CAS Registry No. 419545-30-05
	ChemBridge Product List (17 Jan 2002): Order No. 6064715; CAS Registry No. 298230-06-05
	ChemBridge Product List (17 Jan 2002): Order No. 5678372; CAS Registry No. 419550-75-07
	Scientific Exchange Product List (1 Jan 2003): Order No. POD_42/0901; CAS Registry No. 339253-95-01
	Scientific Exchange Product List (1 Jan 2003): Order No. POD_76/0070; CAS Registry No. 333352-65-01
	Scientific Exchange Product List (1 Jan 2003): Order No. POD_40/0451; CAS Registry No. 331670-05-04

*Examiner

Date Considered

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of next communication to application.

Form PTO-FB-A820 (Also PT

Sheet 2 of 2

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-288

10/766,030

APPLICANT

OXFORD et al

(Use several sheets if necessary)

FILING DATE

GROUP

January 29, 2004

Unassigned

FOREIGN PATENT DOCUMENTS

					TRANSLATION	
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Interchim Intermediates (9 Jul 2002): Order No. BAS 0790464; CAS Registry No. 333352-65-01
	Interchim Intermediates (9 Jul 2002): Order No. STOCK2S-97502; CAS Registry No. 339253-95-01
	Interchim Intermediates (9 Jul 2002): Order No. BAS 0790281; CAS Registry No. 333352-32-02
	Interchim Intermediates (9 Jul 2002): Order No. BAS 0394974; CAS Registry No. 331670-05-04
	Interchim Intermediates (9 Jul 2002): Order No. BAS 0394969; CAS Registry No. 331670-03-02
	Interchim Intermediates (9 Jul 2002): Order No. 8002-0804; CAS Registry No. 339219-13-05
	Screening Collection (28 Mar 2000): Order No. A0240/0010807; CAS Registry No. 333352-32-02
	Screening Collection (28 Mar 2000): Order No. A0973/0045487; CAS Registry No. 339253-95-01
	Screening Collection (28 Mar 2000): Order No. A0177/0007972; CAS Registry No. 333352-65-01
	Screening Collection (28 Mar 2000): Order No. A0240/0010802; CAS Registry No. 298230-06-05
	Screening Collection (28 Mar 2000): Order No. A0240/0010804; CAS Registry No. 339219-13-05
	TimTec Stock Library (19 May 2003): Order No. ST4077305; CAS Registry No. 298230-06-05
	TimTec Stock Library (19 May 2003): Order No. ST4002638; CAS Registry No. 339219-13-05
	ChemDiv, Inc. Product Library (25 Apr 2003): Order No. 8002-0802; CAS Registry No. 298230-06-05
	ChemDiv, Inc. Product Library (25 Apr 2003): Order No. 8002-0804; CAS Registry No. 339219-13-05
	Ambinter: Exploratory Library (30 Apr 2003): Order No. A0240/0010802; CAS Registry No. 298230-06-05
	Ambinter: Exploratory Library (30 Apr 2003): Order No. A0240/0010804; CAS Registry No. 339219-13-05
	Enamine Product Listing (15 Nov 2001): T0400-0794; CAS Registry No. 296273-50-02
	Enamine Product Listing (15 Nov 2001): T0400-2207; CAS Registry No. 297137-48-05
	LaboTest Stock (2 Jan 2002): Order No. LT00150860; CAS Registry No. 331670-05-04
	CAS No. 462078-74-6 (2003)
	CAS No. 438034-05-0 (2003)
	CAS No. 383379-03-1 (2003)
	CAS No. 383172-85-8 (2003)
	CAS No. 339253-95-1 (2003)
	CAS No. 339235-50-6 (2003)
	CAS No. 333352-65-1 (2003)
	CAS No. 333352-32-2 (2003)
	CAS No. 331670-05-4 (2003)
	CAS No. 331670-03-2 (2003)
	CAS No. 297137-48-5 (2003)
	CAS No. 296273-50-2 (2003)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.